Загрузка...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Сохранить в:
| Опубликовано в: : | Cochrane Database Syst Rev |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Ltd
2021
|
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8092423/ https://ncbi.nlm.nih.gov/pubmed/33930176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|